LAPELGA, NEUTROPEG (Apotex Pty Ltd)
Product name
LAPELGA, NEUTROPEG
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
183 working days (255)
Active ingredients
pegfilgrastim
Registration type
New biosimilar medicine
Indication
LAPELGA, NEUTROPEG (solution for injection) are indicated for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and so reduce the incidence of infection, as manifested by febrile neutropenia.